QNTM:NASDAQQuantum Biopharma Ltd. analysis
Data as of Oct 22, 2026 - not real-time
- Latest price
- $2.34
- Risk: high
- 9/10High risk
Summary
At $2.34, Quantum BioPharma Ltd. shows a bearish moving-average alignment, with shorter averages beneath longer ones. Across the trailing 30 sessions it lost 28.9%. With RSI at 27.6 the momentum picture is oversold, alongside a bearish MACD signal. The recent range runs from support at $2.31 up to resistance at $4.00.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 431.7% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 65.3%, a beta of 0.52 and a maximum drawdown of 85.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 89 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Consensus targets land 431.7% above where the shares trade now.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 65.3%, a beta of 0.52 and a maximum drawdown of 85.5%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 89 on the fear-greed composite.
Short, medium and long-term reads agree on hold, with conviction of 1/10.
Top market events
- NEW YORK, Sept. 11, 2026 GLOBE NEWSWIRE -- via BioMedWire — Quantum BioPharma Ltd. NASDAQ: QNTM today announces its...
- NEW YORK, June 23, 2026 GLOBE NEWSWIRE -- via BioMedWire — Quantum BioPharma Ltd.
- Austin, Texas, October 6th, 2026, FinanceWireQuantum BioPharma NASDAQ: QNTM entered into a Study Start-Up Agreement...
Market outlook
Short term
< 1 yearNeutral
Model confidence3/103 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 27.6 signals oversold conditions
- Trading below the 200-day average of 4.03
Medium term
1–3 yearsNeutral
Model confidence2/102 out of 10
Key factors
- Short-term moving averages stacked below long-term ones
- RSI at 27.6 signals oversold conditions
- Trading below the 200-day average of 4.03
Long term
> 3 yearsNeutral
Model confidence1/101 out of 10
Key factors
- Analyst targets imply +431.7% versus the current price
- Negative return on equity of -621.5%
- Negative free cash flow
Key metrics
Financial health
P/E Ratio-0.3
ROE-621.46%
ROA-51.84%
Debt/Equity15.81
P/B Ratio2.2
Op. Cash Flow$-5485545
Free Cash Flow$-5031993
Industry P/E32.3
Technical analysis
TrendBearish
RSI27.6
Support$2.31
Resistance$4.00
MA 20$3.04
MA 50$3.26
MA 200$4.03
MACDBearish
VolumeDecreasing
Fear & Greed Index89.25
Valuation
Target Price$12.44
Upside/Downside431.69%
GradeFair
TypeBlend
Risk assessment
Beta0.52
Volatility65.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.